Type 2 diabetes mellitus, glycemic control, and cancer risk

European Journal of Cancer Prevention

Volumn 23, Issue 2, 2014, Pages 134-140

  Onitilo, Adedayo A ^a,b   Stankowski, Rachel V ^a   Berg, Richard L ^a   Engel, Jessica M ^a   Glurich, Ingrid ^a   Williams, Gail M ^b   Doi, Suhail A ^b  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

cancer; diabetes mellitus; glycemic control; incidence; risk; type 2

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; COLON CANCER; COMORBIDITY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSURANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION; SMOKING;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84893786030     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3283656394     Document Type: Article

References (21)

1. American Diabetes Association (2010). Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62-S69.
2. Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, Suissa S (2011). Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20:337-344.
3. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P (2013). Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 16:151-158.
4. Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, et al. (2011). Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 60:1363-1371.
5. Bodmer M, Becker C, Meier C, Jick SS, Meier CR (2011). Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 123:200-204.
6. Bodmer M, Becker C, Meier C, Jick SS, Meier CR (2012a). Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol 107:620-626.
7. Bodmer M, Becker C, Meier C, Jick SS, Meier CR (2012b). Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 21:280-286.
8. Currie CJ, Poole CD, Gale EA (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777.
9. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012). Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299-304.
10. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, et al. (2008). Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 93:34-40.
11. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH,Yeung SC (2012). Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 23:1771-1780.
12. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. (2009). Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302.
13. Johnson JA, Bowker SL (2011). Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54:25-31.
14. Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E (2008). Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 19:703-710.
15. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625.
16. Masur K, Vetter C, Hinz A, Tomas N, Henirch H, Niggemann B, et al. (2011). Diabetogenic glucose concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer 104:345-352.
17. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ, et al. (2008). Translating the A1c assay into estimated average glucose values. Diabetes Care 31:1473-1478.
18. Nguyen SP, Bnet S, Chen Y-H, Terdiman JP (2009). Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and metaanalysis. Clin Gastroenterol Hepatol 7:676-681.
19. Niv Y, Hazazi R, Levi Z, Fraser G (2008). Screening colonoscopy for colorectal cancer in asymptomatic people: a meta-analysis. Dig Dis Sci 53:3049-3054.
20. Onitilo AA, Engel JM, Glurich I, Stankowski RV, Williams GM, Doi SA (2012). Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 23:991-1008.
21. Taubes G (2012). Cancer research. Ravenous for glucose. Science 335:31.